Skip to main content

Table 1 Baseline patient characteristics

From: Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

  Total (n = 314) Good responders (n = 92) Poor responders (n = 222) P-value
Age, years, mean ± SD 59.1 ± 10.1 59.2 ± 10.1 59.1 ± 10.1 0.953
Sex, Female 145 (46.2) 53 (57.6) 92 (41.4) 0.009
History of smoking (n = 303) 303 86 217 0.015
 Current smoker 68 (22.4) 12 (14.0) 56 (25.8)  
 Ex-smoker 76 (25.1) 18 (20.9) 58 (26.7)
 Never smoker 159 (52.5) 56 (65.1) 103 (47.5)  
Stage     0.456
 ≤IIIB 19 (6.1) 7 (7.6) 12 (5.4)  
 IV 295 (93.9) 85 (92.4) 210 (94.6)  
  Stage M1a 93 (29.6) 44 (47.8) 49 (22.1) <0.001
  Stage M1b 202 (64.3) 41 (44.6) 161 (72.5) <0.001
Type of chemotherapy     0.002
 Pemetrexed monotherapy 263 (83.8) 68 (73.9) 195 (87.8)  
 Pemetrexed combination 51 (16.2) 24 (26.1) 27 (12.2) 0.552
  Platinum 34 (10.8) 15 (16.3) 19 (8.6)  
  Non-platinum 17 (5.4) 9 (9.8) 8 (3.6)  
Previous chemotherapy     0.068
 0 44 (14.0) 18 (19.6) 26 (11.7)  
 ≥1 270 (86.0) 74 (80.4) 196 (88.3)  
Previous regimen (n = 270)a 270 74 196  
 Response to Gemcitabineb 88/175 (50.3) 32/49 (65.3) 56/126 (44.4) 0.013
 Response to EGFR-TKI 79/128 (61.7) 16/34 (47.1) 63/94 (67.0) 0.040
 Response to Paclitaxel 36/56 (64.3) 5/14 (35.7) 31/42 (73.8) 0.010
 Response to Docetaxel 7/14 (50.0) 4/6 (66.7) 3/8 (37.5) 0.592
 Response to Miscellaneous 7/15 (46.7) 3/4 (75.0) 4/11 (36.4) 0.282
  1. Data are shown as n (%) per each group, unless otherwise noted
  2. aTotal number exceeds 270 as some patients had received two or more regimen prior to pemetrexed
  3. bResponse was defined as achievement of partial response or stable disease for 3 months or more. Others were defined as non-response
  4. SD standard deviation, EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor